Olaparib for the treatment of breast cancer.

Abstract:

INTRODUCTION:Mutations in BRCA1 and BRCA2 genes account for around 2-3% of breast cancer events and more than 10% of triple negative breast cancers. Olaparib (Lynparza®), an orally administered PARP inhibitor, demonstrated clinical benefit in a phase III trial for mutated BRCA-positive HER2 negative metastatic breast cancer. Areas covered: This review gives an overview of available preclinical and clinical data regarding olaparib, including its chemistry, mechanism of action, pharmacokinetics and pharmacodynamics, and evidence supporting antitumor efficacy and safety profile in breast cancer patients. Expert commentary: Olaparib improves progression-free survival in germline BRCA mutated HER2 negative metastatic breast cancer patients as compared to standard chemotherapy, with a manageable toxicity profile. Efficacy is of clinical relevance especially in the context of triple negative breast cancer. However, several aspects, such as sequencing or combination of these agents with other anticancer agents and identification of appropriate biomarkers, still need to be clearly defined.

authors

Griguolo G,Dieci MV,Guarneri V,Conte P

doi

10.1080/14737140.2018.1458613

subject

Has Abstract

pub_date

2018-06-01 00:00:00

pages

519-530

issue

6

eissn

1473-7140

issn

1744-8328

journal_volume

18

pub_type

杂志文章,评审
  • Dermoscopy in the era of dermato-oncology: from bed to bench side and retour.

    abstract::Today dermoscopy is standard-of-care in the diagnosis and management of patients with benign and malignant skin tumors because it increases the diagnostic accuracy of skin lesions compared to the naked-eye examination up to 25%. Despite its role in the routine dermato-oncology, it increasingly gained interest as a bri...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.2016.1168700

    authors: Woltsche N,Schwab C,Deinlein T,Hofmann-Wellenhof R,Zalaudek I

    更新日期:2016-05-01 00:00:00

  • Laparoscopic colorectal cancer surgery.

    abstract::Colorectal cancer remains the second most common cause of cancer death in the USA and western Europe, with more than 34,000 new cases per year in the UK alone. Annual expenditure is in excess of pounds sterling 300 million, required for surgical, adjuvant and palliative treatment. Laparoscopic colorectal surgery has y...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.3.4.484

    authors: Macafee DA,Maxwell-Armstrong C,Scholefield JH

    更新日期:2003-08-01 00:00:00

  • Breast cancer chemoprevention.

    abstract::According to the National Cancer Institute Surveillance Epidemiology and End Results Cancer Statistics Review, the incidence of invasive breast cancer in the USA is 124 women per 100,000 population. Women at increased risk for breast cancer have three major options to reduce their risk, specifically screening, chemopr...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.11.206

    authors: Gabriel EM,Jatoi I

    更新日期:2012-02-01 00:00:00

  • Advances in radiation therapy of head and neck cancer.

    abstract::Head and neck cancer is the fifth most common cancer in the USA. Although there have been major improvements in surgical and radiation techniques, the overall survival has not changed significantly in the last decade. The major changes occurring in recent years have been in the ability to preserve organs and to improv...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.8.4.633

    authors: Popovtzer A,Eisbruch A

    更新日期:2008-04-01 00:00:00

  • Metastases of colorectal cancer to the liver and peritoneum: comparison of surgical paradigms.

    abstract::The treatment of metastatic colorectal cancer is evolving. Although the advent of new chemotherapeutic and biologic agents has certainly improved the outlook for many patients, surgical resection in certain subsets of patients with advanced colorectal cancer is the only chance for long-term survival. Traditionally, pa...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.8.11.1797

    authors: Shen P,Stewart JH,Levine EA

    更新日期:2008-11-01 00:00:00

  • Primary systemic therapy in HER2-amplified breast cancer: a clinical review.

    abstract::Primary systemic therapy (PST) in early breast cancer is utilized in locally advanced breast tumors and when breast-conserving surgery is desirable. In addition, the PST setting provides an opportunity to monitor response including histopathological and biomarker examination of the tumor and host tissues before and af...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.12.62

    authors: Khasraw M,Bell R

    更新日期:2012-08-01 00:00:00

  • Small cell carcinoma of the urinary bladder: a contemporary review with a special focus on bladder-sparing treatments.

    abstract::Small cell carcinoma of the urinary bladder (SCCUB) is a rare and aggressive disease. To date, no standard treatment has been proposed due to the lack of prospective studies resulting from the rarity of this disease. Recently published studies of relatively large patient cohorts, however, have shed some light on the m...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.2013.851605

    authors: Koga F,Yokoyama M,Fukushima H

    更新日期:2013-11-01 00:00:00

  • Benefits of laparoscopic prostate-sparing radical cystectomy.

    abstract:PURPOSE:Prostate-sparing radical cystectomy has been described in the literature and has proven to be a promising procedure owing to the continence and erectile function results without necessarily compromising the oncologic outcome in selected patients. TECHNIQUE POINTS:A transperitoneal approach is used. Lymph node ...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.6.1.21

    authors: Rozet F,Harmon J,Arroyo C,Cathelineau X,Barret E,Vallancien G

    更新日期:2006-01-01 00:00:00

  • Notch signaling in lung cancer.

    abstract::Lung cancer is the leading cause of cancer-related deaths in the Western world. The lungs can be affected by a number of histologically diverse malignancies. Nonetheless, the vast majority of lung cancers are classified as non-small-cell lung cancer (NSCLC). Despite extensive research on different therapeutic regimens...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.10.158

    authors: Galluzzo P,Bocchetta M

    更新日期:2011-04-01 00:00:00

  • Treatment options for advanced pancreatic cancer: a review.

    abstract::Advanced pancreatic adenocarcinoma historically has a poor prognosis and the mortality rate has remained unchanged for over a decade. Common treatment options for patients with advanced pancreatic cancer include chemoradiation and/or chemotherapy. Single-agent gemcitabine has been considered the standard of care since...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.12.115

    authors: Warsame R,Grothey A

    更新日期:2012-10-01 00:00:00

  • Finding needles in a haystack: annual low-dose computed tomography screening reduces lung cancer mortality in a high-risk group.

    abstract::Lung cancer is a global health issue. Compared with other common malignancies, the prognosis is poor as many patients present with advanced disease. The National Lung Screening Trial (NLST) aimed to identify and treat early lung cancers using annual low-dose computed tomography (CT) screening in a high-risk group. Whe...

    journal_title:Expert review of anticancer therapy

    pub_type: 评论,杂志文章

    doi:10.1586/era.11.185

    authors: Duke SL,Eisen T

    更新日期:2011-12-01 00:00:00

  • TIM-3 pathway dysregulation and targeting in cancer.

    abstract:INTRODUCTION:Dysfunction of the immune system is a hallmark of cancer. Through increased understanding of the complex interactions between immunity and cancer, immunotherapy has emerged as a treatment modality for different types of cancer. Promising activity with immunotherapy has been reported in numerous malignancie...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章

    doi:10.1080/14737140.2021.1865814

    authors: Zeidan AM,Komrokji RS,Brunner AM

    更新日期:2021-01-19 00:00:00

  • Optimal management of pulmonary metastases from colorectal cancer.

    abstract::The incidence of colorectal cancers is rising worldwide and pulmonary metastases were seen in approximately 10-15% of all patients. Surgical metastasectomy is a widely accepted procedure in selected patients and is considered as the only curative option in patients with secondary pulmonary malignancy. But surgical res...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.11.123

    authors: Limmer S,Unger L

    更新日期:2011-10-01 00:00:00

  • Transsphenoidal microsurgery: past, present and future.

    abstract::In this report, we first describe the history of transsphenoidal surgery. We further elaborate on three fundamental surgical anatomy principles of transsphenoidal surgery for pituitary adenomas. First, the pituitary gland and, therefore, pituitary adenomas are extra-arachnoid structures, therefore the operation should...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.6.9s.S75

    authors: Ciric IS,Zhao J

    更新日期:2006-09-01 00:00:00

  • The role of surgery in recurrent endometrial cancer.

    abstract:INTRODUCTION:Endometrial cancer is a common gynecologic malignancy in the United States, and the recurrence rate depends on the disease stage at diagnosis. Recurrence can affect several areas and follow different patterns. AREAS COVERED:The role of surgery at the time of recurrence is not clearly defined. In this revi...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1080/14737140.2016.1190650

    authors: Zanfagnin V,Ferrero A,Biglia N,Aletti G,Gill SE,Makdisi PB,Multinu F,Mariani A

    更新日期:2016-07-01 00:00:00

  • Venous thromboembolism and malignancy.

    abstract::The association between venous thromboembolism (VTE) and malignancy was first recognized more than 135 years ago. Since then, a markedly increased incidence of VTE has been found in patients with malignant disease. Numerous clinical studies have demonstrated that malignancy or its treatment are major risk factors for ...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.4.2.303

    authors: Gao S,Escalante C

    更新日期:2004-04-01 00:00:00

  • Nonmyeloablative transplantation for solid tumors: a new frontier for allogeneic immunotherapy.

    abstract::The failure of conventional chemotherapy to improve survival in a large percentage of patients with advanced solid tumors has prompted the development of alternative anticancer approaches. Conventional allogeneic hematopoietic stem cell transplantation (HSCT) relies on myeloablative conditioning to eradicate the under...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.4.5.865

    authors: Espinoza-Delgado I,Childs RW

    更新日期:2004-10-01 00:00:00

  • The safety and efficacy of ramucirumab in combination with docetaxel in the treatment of lung cancer.

    abstract:INTRODUCTION:Angiogenesis is critical for tumor growth, proliferation and metastasis with the crucial role of Vascular Endothelial Growth factor (VEGF) pathway. Ramucirumab is a monoclonal antibody that specifically targets the extracellular domain of Vascular Endothelial Growth Factor Receptor 2. Areas covered: We per...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章

    doi:10.1080/14737140.2016.1241147

    authors: Paulus V,Avrillon V,Pérol M

    更新日期:2016-11-01 00:00:00

  • Satraplatin: an orally available platinum analog for the treatment of cancer.

    abstract::Satraplatin is a novel, orally bioavailable, platinum anticancer drug. Platinum analogs form the mainstay of treatment for a number of cancers, including lung, ovarian, colorectal and head and neck cancer. A disadvantage of the currently marketed platinum analogs is that they must all be administered via intravenous i...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.6.7.973

    authors: Choy H

    更新日期:2006-07-01 00:00:00

  • Health-related quality of life in cancer patients treated with PD-(L)1 inhibitors: a systematic review.

    abstract:INTRODUCTION:A systematic review was performed to explore the health-related quality of life (HRQoL) outcomes among cancer patients receiving PD-(L)1 inhibitors compared to those receiving traditional cytotoxic therapy. Areas covered: Citations from PubMed and the American Society of Clinical Oncology meeting library w...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章

    doi:10.1080/14737140.2018.1528146

    authors: Abdel-Rahman O,Oweira H,Giryes A

    更新日期:2018-12-01 00:00:00

  • The LUX-Lung clinical trial program of afatinib for non-small-cell lung cancer.

    abstract::Epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) represents a distinct disease entity whose molecular phenotype predicts exquisite sensitivity to the reversible EGFR-tyrosine kinase inhibitors (TKIs) gefitinib or erlotinib. However, primary or acquired resistance to these agents remain...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1586/era.11.34

    authors: Metro G,Crinò L

    更新日期:2011-05-01 00:00:00

  • The evolving role of receptors as predictive biomarkers for metastatic breast cancer.

    abstract:INTRODUCTION:In breast cancer, estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2) are essential biomarkers to predict response to endocrine and anti-HER2 therapies, respectively. In metastatic breast cancer, the use of these receptors and targeted therapies present additional challenges: tempora...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1080/14737140.2019.1552138

    authors: Martínez-Pérez C,Turnbull AK,Dixon JM

    更新日期:2019-02-01 00:00:00

  • Genetic polymorphisms and endometrial cancer risk.

    abstract::For most sporadic cancers, genetic susceptibility results from the additive effect of multiple genetic variants, each of which contributes a modest risk individually. The study of genetic single nucleotide polymorphisms (SNPs) may help explain the differences in individual cancer susceptibility and may assist in ident...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.8.7.1159

    authors: Meyer LA,Westin SN,Lu KH,Milam MR

    更新日期:2008-07-01 00:00:00

  • Cladribine in indolent non-Hodgkin's lymphoma.

    abstract::Before the advent of rationally designed targeted antineoplastic therapies, cladribine was identified as a lymphocyte-specific cytotoxic agent. Cladribine is a purine nucleoside analogue that is resistant to cellular catabolism. Through diverse mechanisms, cladribine is equally toxic to dividing and nondividing cells,...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.8.4.535

    authors: Sigal DS,Saven A

    更新日期:2008-04-01 00:00:00

  • Use of angiotensin-converting enzyme inhibitors in the prophylaxis of anthracycline or trastuzumab-related cardiac dysfunction: preclinical and clinical considerations.

    abstract::Cardiac toxicity is one of the most important long-term toxicities experienced by cancer survivors so that survival rate due to anticancer therapy may be negatively affected due to cardiac complications. Thus, the search for novel methods to lower the incidence of treatment-related cardiotoxicity is a priority for all...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.2015.1047766

    authors: Abdel-Rahman O,Alorabi M

    更新日期:2015-01-01 00:00:00

  • New treatment strategies for malignant gliomas.

    abstract::Malignant gliomas are the most prevalent type of primary brain tumor in adults. Despite progress in brain tumor therapy, the prognosis of malignant glioma patients remains dismal. The median survival of patients with glioblastoma multiforme, the most common grade of malignant glioma, is 10-12 months. Conventional ther...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.6.7.1087

    authors: Sathornsumetee S,Rich JN

    更新日期:2006-07-01 00:00:00

  • Biomarkers for prostate cancer detection.

    abstract::Since its approval by the US FDA in 1986, prostate-specific antigen (PSA) has been employed to monitor men with a diagnosis of prostate cancer. In 1994, PSA was approved for use in prostate cancer screening and has been employed worldwide. However, due to the limited specificity of PSA for the disease, novel biomarker...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.09.168

    authors: Reed AB,Parekh DJ

    更新日期:2010-01-01 00:00:00

  • The addition of gemtuzumab ozogamicin to chemotherapy in adult patients with acute myeloid leukemia.

    abstract::The treatment of acute myeloid leukaemia has remained largely unchanged for the last 30 years since the advent of combination chemotherapy with cytarabine arabinoside and daunorubicin with remission rates around 70% but with long term survival still only around 40% in young adults. Doses of chemotherapy have been push...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章

    doi:10.1586/14737140.2016.1162099

    authors: Kell J

    更新日期:2016-01-01 00:00:00

  • CyberKnife robotic radiosurgery system for tumor treatment.

    abstract::Defined by its high level of accuracy and rapid radiation dose fall-off, radiosurgery has emerged as an effective radiation technique over the past few decades. Although it was once limited to conditions of the brain, head and neck regions, technological advances in computing and imaging have allowed the application o...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.7.11.1507

    authors: Hara W,Soltys SG,Gibbs IC

    更新日期:2007-11-01 00:00:00

  • Atrasentan: a novel and rationally designed therapeutic alternative in the management of cancer.

    abstract::Endothelin axis deregulation triggers a series of events that ultimately activate proliferation, invasion, escape from programmed cell death, new vessel formation, abnormal osteogenesis and alteration of nociceptive stimuli. Atrasentan is a novel agent that effectively targets this pathway and is able to inhibit and/o...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.5.3.419

    authors: Jimeno A,Carducci M

    更新日期:2005-06-01 00:00:00